Agenus Inc. develops immuno-oncology therapies for cancer, with recurring updates centered on botensilimab (BOT) and balstilimab (BAL), its CTLA-4/PD-1 immunotherapy combination. Company news regularly covers clinical data in solid tumors, including metastatic colorectal cancer, melanoma and gastroesophageal cancer, as well as translational biomarker work and combination approaches that use antibody therapeutics, adoptive cell therapy through MiNK Therapeutics and adjuvants.
Agenus updates also address regulatory-authorized access pathways for BOT+BAL, including France's AAC framework and paid named-patient programs where permitted, along with financial results, equity financing activity, commercial readiness, manufacturing collaborations and corporate governance developments.
Agenus (NASDAQ: AGEN) announces Dr. Steven O’Day's participation in a panel discussion on immuno-oncology at William Blair’s Biotech Focus Conference on July 12, 2022, at 4:10 PM EST. The conference will be held from July 12-13, 2022, at The St. Regis New York hotel, where Agenus will also conduct one-on-one investor meetings. Agenus focuses on developing therapies that harness the body's immune system to combat cancer and infections, aiming to expand patient access to cancer immunotherapy through innovative combinations and advanced manufacturing capabilities.
Agenus (NASDAQ: AGEN) has reported promising results from its Phase 1b study of botensilimab and balstilimab in patients with microsatellite stable colorectal cancer (MSS CRC). Key findings include a 24% overall response rate and a 73% disease control rate, with 80% of responses ongoing at data cutoff. The combination therapy has shown durability, especially in heavily pre-treated patients. A global Phase 2 study is set to begin this year, building on the strong therapeutic potential demonstrated in cold tumors.
Agenus (NASDAQ: AGEN) announced it will host a hybrid webcast on June 29, 2022, at 10:00 AM EST to discuss botensilimab/balstilimab combination data in microsatellite stable colorectal cancer (MSS-CRC). This data was presented earlier at the ESMO World Congress in Barcelona. The webcast features speakers including Steven O’Day, M.D., and Dr. Anthony El-Khoueiry, among others. Interested attendees can register through the Investors section of the Agenus website. An archived version will be available post-event.
Agenus (NASDAQ: AGEN) announces that their partner GSK's RSV vaccine candidate has shown significant efficacy in adults aged 60 and older in the AReSVi 006 phase III trial. The primary endpoint was met with no safety concerns. Anticipated global regulatory submissions are set for H2 2022. This vaccine contains QS-21 STIMULON, an adjuvant noted for its effectiveness in vaccines like Shingrix. Additionally, Agenus subsidiary SaponiQx is developing eco-friendly manufacturing processes for QS-21 STIMULON, aiming to support broad vaccine production, including responses to pandemics.
Agenus Inc. (NASDAQ: AGEN) has announced three new clinical collaborations, doubling its partnerships in immuno-oncology. Collaborations involve Targovax, Oxford BioTherapeutics, and Immunogenesis, targeting various cancers with a focus on optimizing immunotherapy combinations. The trials will explore synergistic effects of Agenus' candidates like botensilimab and balstilimab alongside other agents. This strategy aims to enhance treatment efficacy for patients with treatment-resistant solid tumors, leveraging Agenus' manufacturing and scientific capabilities.
Agenus (NASDAQ: AGEN) has announced its Annual Shareholders Meeting set for June 8, 2022, at 3:30 p.m. ET, to be held virtually. Shareholders can register from 3:15 p.m. ET via a control number found in proxy materials. The meeting will be accessible in listen-only mode for non-shareholders. Agenus focuses on immuno-oncology, developing therapies that engage the immune system against cancer and infections, utilizing a range of advanced platforms and facilities.
Agenus (NASDAQ: AGEN), a clinical-stage immuno-oncology company, announced that Dr. Garo Armen and Dr. Steven O’Day will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 11:30 AM EST. The event will take place at the New York Marriott Marquis from June 8-10. One-on-one meetings with investors will also be available. A webcast of the chat can be accessed for 90 days post-event. Agenus focuses on therapies that engage the immune system to combat cancer and infections.
Agenus Inc. (NASDAQ: AGEN) announces botensilimab's late-breaking presentation at the ESMO World Congress on Gastrointestinal Cancer, focusing on treating heavily pretreated MSS colorectal cancer. The company also reveals a strategic plan to cut operating costs by 20% in 2022. Positive clinical responses were highlighted, with botensilimab and balstilimab showing efficacy in difficult-to-treat patients. Agenus aims to accelerate development and prioritize high-potential programs while enhancing operational efficiencies through advanced technologies.
Agenus Inc. (NASDAQ: AGEN) announced significant clinical advancements in its immuno-oncology pipeline. The company is set to initiate Phase 2 trials for botensilimab targeting colorectal, melanoma, and pancreatic cancers, with data updates expected in Q3. AGEN1571 trials will commence following its presentation at AACR, while AGEN2373 is progressing, evidenced by a $5 million milestone payment from Gilead, with potential future payments up to $570 million. Financially, Agenus reported $26 million in revenue for Q1 2022, an increase of $14 million year-over-year, and a net loss of $51 million.
Agenus (NASDAQ: AGEN) will release its Q1 2022 financial results on May 10, 2022, before market opening. The company focuses on immuno-oncology, developing therapies that leverage the immune system against cancer. A conference call and webcast are scheduled for the same day at 8:30 a.m. ET to discuss results and offer a corporate update. The call can be accessed via dial-in numbers provided, and a replay will be available on the company's website. For more information, visit www.agenusbio.com.